Abstract:Mexiletine, a class Ib antiarrhythmic agent, is rapidly and completely absorbed following oral administration with a bioavailability of about 90%. Peak plasma concentrations following oral administration occur within 1 to 4 hours and a linear relationship between dose and plasma concentration is observed in the dose range of 100 to 600 mg. Mexiletine is weakly bound to plasma proteins (70%). Its volume of distribution is large and varies from 5 to 9 L/kg in healthy individuals. Mexiletine is eliminated slowly in humans (with an elimination half-life of 10 hours). It undergoes stereoselective disposition caused by extensive metabolism. Eleven metabolites of mexiletine are presently known, but none of these metabolites possesses any pharmacological activity. The major metabolites are hydroxymethyl-mexiletine, p-hydroxy-mexiletine, m-hydroxy-mexiletine and N-hydroxy-mexiletine. Formation of hydroxymethyl-mexiletine, p-hydroxy-mexiletine and m-hydroxy-mexiletine is genetically determined and cosegregates with polymorphic debrisoquine 4-hydroxylase [cytochrome P450 (CYP) 2D6] activity. On the other hand, CYP1A2 seems to be implicated in the N-oxidation of mexiletine. Various physiological, pathological, pharmacological and environmental factors influence the disposition of mexiletine. Myocardial infarction, opioid analgesics, atropine and antacids slow the rate of absorption, whereas metoclopramide enhances it. Rifampicin (rifampin), phenytoin and cigarette smoking significantly enhance the rate of elimination of mexiletine, whereas ciprofloxacin, propafenone and liver cirrhosis decrease it. Cimetidine, ranitidine, fluconazole and omeprazole do not modify the disposition of mexiletine. Conversely, mexiletine is known to alter the disposition of other drugs, such as caffeine and theophylline. Factors affecting the elimination of mexiletine may be clinically important and dosage adjustments are often necessary.

Pharmacokinetics of tiapride and absolute bioavailability of three extravascular forms

[Treatment of headache with tiapride (author's transl)]

[Effect of tiapride on headache and various other types of pain]

[Pharmacokinetics and Relative Bioavailability of Ziprasidone Tablets in Chinese Healthy Volunteers].

Bioequivalance of tropisetron granule in healthy volunteers after a single oral administration

[Tiapride and rehabilitation (author's transl)]

Absorption and Metabolism Characteristics of Triptolide as Determined by a Sensitive and Reliable LC-MS/MS Method

Determination of tiopronin in human plasma and study on its bioequivalence

Pharmacokinetics of the P-gp Inhibitor Tariquidar in Rats After Intravenous, Oral, and Intraperitoneal Administration

Relative bioavailability of dipyridamole compound recipe extended-release capsules in healthy volunteers

[Tiapride and alcoholism]

Relative bioavailability of metoprolol tartrate extended release tablets

Pharmacokinetics of ,4-dichlorophenyl-propenoyl-sec. -butylamine (7903) in rats

Pharmacokinetics and Bioequivalence of a Generic Ticagrelor 90‐mg Formulation Versus the Innovator Product in Healthy White Subjects Under Fasting Conditions

Gender-related Differences in Pharmacokinetics of Novel Prodrug of Triptolide MC002 in Rats

Comparative bioavailability of trazodone formulations using stable isotope methodology

[Effect of tiapride in acute manifestations of alcohol withdrawal]

Clinical pharmacokinetics of mexiletine

Safety, tolerability and pharmacokinetics of the phosphodiesterase 2 inhibitor BI 474121: An overview of phase I randomized trials in healthy volunteers

Evaluation of Bioequivalence of Mirtazapine Tablets

Evaluation of the Bioequivalence and Pharmacokinetics of Two Formulations of Rizatriptan after Single Oral Administration in Healthy Volunteers